Santen Pharmaceutical recorded sales of 291.6 billion yen (YoY \u25b32.8%) for the fiscal year ending March 2026, with core operating profit of 55.1 billion yen (\u25b37.1%). Net income attributable to owners of the parent was 37.6 billion yen (+4.8%), and dividends are scheduled to increase to 38 yen annually. The company anticipates continued revenue growth and profit expansion next term, focusing on expanding overseas operations.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4536","jir_company_name":"Santen Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4536-20260512-01.pdf","jir_short_summary":"Santen Pharmaceutical recorded sales of 291.6 billion yen (YoY \u25b32.8%) for the fiscal year ending March 2026, with core operating profit of 55.1 billion yen (\u25b37.1%). Net income attributable to owners of the parent was 37.6 billion yen (+4.8%), and dividends are scheduled to increase to 38 yen annually. The company anticipates continued revenue growth and profit expansion next term, focusing on expanding overseas operations.","jir_summary":"### Performance Overview\nFor the fiscal year ending March 2026, Santen Pharmaceutical achieved sales of 291.6 billion yen (\u25b32.8%) and core operating profit of 55.1 billion yen (\u25b37.1%), showing slight declines. However, net income increased to 37.6 billion yen (+4.8%) due to expansion of flagship products and steady growth in overseas markets. The company plans to increase dividends to 38 yen and aims for continued revenue and profit growth next year. Strategic initiatives focus on strengthening domestic and international business operations.\n\n### Impact on Shareholders and Future Outlook\nDividends are scheduled to increase to 38 yen annually, reflecting a focus on shareholder returns. For the next term, sales are expected to reach approximately 311.0 billion yen (+6.6%), with core operating profit of 59.0 billion yen (+7.0%), indicating ongoing revenue and profit growth. The company will remain vigilant to exchange rate fluctuations and market conditions, advancing proactive business investments and efficiency measures to sustain growth.","jir_financial_highlights":"Sales Revenue: 291.6 billion yen (YoY \u25b32.8%)\nCore Operating Profit: 55.1 billion yen (YoY \u25b37.1%)\nNet Income Attributable to Owners of the Parent: 37.6 billion yen (YoY +4.8%)\nAnnual Dividends: 38 yen (YoY +6 yen (scheduled increase))","jir_category":"","jir_hashtags":"#SantenPharmaceutical, #IRFinancialResults, #JapanStocks","jir_key_figures":"Sales Revenue: 291.6 billion yen (\u25b32.8%)\nNet Income Attributable to Owners of the Parent: 37.6 billion yen (+4.8%)\nAnnual Dividends: 38 yen (scheduled increase)","jir_meta_title":"\u3010Santen Pharmaceutical\u30112026 Financial Results\uff5cSales of 291.6 billion yen (\u25b32.8%)","jir_meta_description":"Santen Pharmaceutical achieved sales of 291.6 billion yen (\u25b32.8%) and net income of 37.6 billion yen (+4.8%) in the fiscal year ending March 2026. The company anticipates continued revenue and profit growth next term, with a focus on expanding overseas operations.","jir_og_title":"\u3010Santen Pharmaceutical\u30112026 Financial Results\uff5cSales of 291.6 billion yen (\u25b32.8%)","jir_og_description":"Santen Pharmaceutical achieved sales of 291.6 billion yen and net income of 37.6 billion yen for the fiscal year ending March 2026. The company expects ongoing revenue and profit growth, accelerating international expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7842,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48155","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n